Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
spongosine
- Development stage
- Phase 2
- Lead developer
- Sobi
- Modality
- Small Molecules
01
Overview
**Spongosine** (2-methoxyadenosine, CAS 24723-77-1) is a naturally occurring purine nucleoside analog isolated from marine sponges, particularly the Tethyidae family and Cryptotethya crypta. It functions as an antagonist of adenosine receptors (A1, A2A, A3), exhibiting diverse bioactivities including anti-inflammatory effects, analgesic properties, and vasodilation. As a research compound, it has shown potential antitumor activity against indolent lymphoid malignancies typical of purine nucleoside analogs, though it remains preclinical without approved indications.[1][3][7][9]
- Other names
- 2-methoxyadenosine2-methoxy adenosine
02
Targets
ADORA2A (Adenosine A₂A Receptor)ADORA1 (Adenosine receptor A1 subtype)ADORA3 (Adenosine A3 receptor)
Beyond the preview
Go deeper on spongosine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on spongosine.